---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000166"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:19:00.426089+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions appoints DeGolyer and Fowler to board, adopts inducement plan

## Summary
- Donald DeGolyer and Neal Fowler appointed Class III directors effective Oct 1, 2023; terms expire at 2024 annual meeting.
- Both are independent; DeGolyer on Compensation Committee, Fowler on Audit and Finance Committee.
- Each receives initial RSU grant valued at $375,000, vesting in three equal annual installments.
- Board adopted Inducement Plan reserving 5 million shares for equity grants to new hires.

## SEC filing metadata
- accession: 0001367644-23-000166
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/0001367644-23-000166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/ebs-20230928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000166
- JSON: https://secwatch.observer/filing/0001367644-23-000166.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000166.txt

## Key facts
- Executive change
  Neal Fowler was appointed as Class III Director at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/0001367644-23-000166-index.htm
- Executive change
  Donald DeGolyer was appointed as Class III Director at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On September 28, 2023, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Donald DeGolyer and Neal Fowler as Class III directors effective October 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000166/0001367644-23-000166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.